Bioactive Mediator Profile of Mepolizumab-Treated Eosinophilic Granulomatosis With Polyangiitis
Allergy
.
2024 Nov 11.
doi: 10.1111/all.16395.
Online ahead of print.
Authors
Yosuke Kamide
1
,
Kyuto Sonehara
2
,
Kiyoshi Sekiya
1
,
Shigeharu Ueki
3
,
Yuto Nakamura
1
,
Yukinori Okada
2
,
Masami Taniguchi
1
4
Affiliations
1
Clinical Research Center for Allergy and Rheumatology, NHO Sagamihara National Hospital, Sagamihara, Japan.
2
Department of Statistical Genetics, Osaka University Graduate School of Medicine, Suita, Japan.
3
Department of General Internal Medicine and Clinical Laboratory Medicine, Akita University Graduate School of Medicine, Akita, Japan.
4
Research Center for Immunology and Allergology, Shonan-Kamakura General Hospital, Kamakura, Japan.
PMID:
39526755
DOI:
10.1111/all.16395
No abstract available
Grants and funding
UMIN000040163/GlaxoSmithKline
JP22ek0410097/Japan Agency for Medical Research and Development
22K08598/Japan Society for the Promotion of Science (JSPS) KAKENHI
24K11593/Japan Society for the Promotion of Science (JSPS) KAKENHI
202213003A/Ministry of Health, Labour and Welfare